Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Mineralys Therapeutics in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) saw strong trading volume on Wednesday after HC Wainwright ...

Aldosterone is known to bind to these receptors in the kidney and cardiovascular system, increasing blood pressure through increasing sodium reabsorption and probably other mechanisms. The drug is ...

This study offers hope for individuals with uncontrolled and treatment-resistant high blood pressure. Lorundrostat, a new drug that targets a hormone called aldosterone, has shown promise in ...

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed ... and preclinical-stage ROCK2 and aldosterone synthase inhibitors.

A new blood pressure medication called lorundrostat has shown promising results in reducing blood pressure among patients ...

Baxdrostat is a highly selective aldosterone synthase inhibitor; phase 1 studies showed that the therapy caused a sustained, dose-dependent reduction in plasma aldosterone by more than 70% without ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Loss of appetite is also a common problem in people with chronic (long-term) medical conditions, such as cancer, depression, and kidney disease ... to release insufficient amounts of the hormones ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

sNDA accepted for Priority Review Lorundrostat (Mineralys Therapeutics) Highly selective aldosterone synthase inhibitor that reduces aldosterone levels by inhibiting CYP11B2 Treatment of ...